BIOSPECIFICS TECHNOLOGIES CORP - FORM 10-K - EX-32.1 - EXHIBIT 32.1 - March 16, 2020

Attached files

file filename
EX-31.2 - EXHIBIT 31.2 - BIOSPECIFICS TECHNOLOGIES CORPex31_2.htm
EX-31.1 - EXHIBIT 31.1 - BIOSPECIFICS TECHNOLOGIES CORPex31_1.htm
EX-23.1 - EXHIBIT 23.1 - BIOSPECIFICS TECHNOLOGIES CORPex23_1.htm
EX-21.1 - EXHIBIT 21.1 - BIOSPECIFICS TECHNOLOGIES CORPex21_1.htm
EX-10.31 - EXHIBIT 10.31 - BIOSPECIFICS TECHNOLOGIES CORPex10_31.htm
EX-10.30 - EXHIBIT 10.30 - BIOSPECIFICS TECHNOLOGIES CORPex10_30.htm
EX-10.5 - EXHIBIT 10.5 - BIOSPECIFICS TECHNOLOGIES CORPex10_5.htm
EX-4.7 - EXHIBIT 4.7 - BIOSPECIFICS TECHNOLOGIES CORPex4_7.htm
10-K - 10-K - BIOSPECIFICS TECHNOLOGIES CORPform10k.htm
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002
 
In connection with BioSpecifics Technology Corp.’s (the “Company”) Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, J. Kevin Buchi, Chief Executive Officer of the Company, and Patrick Hutchison, Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on each of our knowledge:
 
 
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: March 16, 2020
  
   
 
/s/ J. Kevin Buchi
 
J. Kevin Buchi
 
Chief Executive Officer
   
 
/s/ Patrick Hutchison
 
Patrick Hutchison
 
Chief Financial Officer


Stock widget

Investing forum

BIOSPECIFICS TECHNOLOGIES CORP Reports